Simple and predictive bioassays for potency and dose-standardization are still sought by the biopharmaceutical industry. Automatable, homogeneous bioassays are desirable because they can help to streamline this evaluative process. Implementing straightforward predictive automation-friendly bioassays as demonstrated in this article allows effective assessment of anti-TNFa and likely other biologicals for quality control. This article was reprinted in Promega Notes 100 with permission from Genetic Engineering News.
Promega Notes 100, 19–21.
Sarah Shultz, Andrew Niles, Jey Cheng and Simon T.M. Allard